Clearside Biomedical Inc (CLSD.OQ)
23 Apr 2018
* CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* CLEARSIDE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion
* CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION
* Shares surge 50 pct (Adds comments from analyst and conference call, background; updates share movement)
Drug developer Clearside Biomedical Inc said on Monday its treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study, sending its shares surging 54.1 percent in premarket trading.
March 5 Clearside Biomedical Inc said on Monday its treatment for fluid build-up in the eye had met the main goal of a late-stage study.
* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update
BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
* Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema